IDEXX Laboratories Q3 Adj. EPS $2.50 Beats $2.37 Estimate, Sales $915.53M Miss $926.76M Estimate
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories reported Q3 earnings of $2.50 per share, beating the analyst consensus estimate of $2.37 by 5.49%. This is a 16.28% increase from the same period last year. However, the company's quarterly sales of $915.53 million missed the analyst consensus estimate of $926.76 million by 1.21%, though it's an 8.78% increase from last year.
November 01, 2023 | 10:35 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IDEXX Laboratories reported better-than-expected Q3 earnings but missed on sales. The earnings beat might boost investor confidence, while the sales miss could raise concerns.
IDEXX Laboratories reported a strong Q3 earnings beat, which could boost investor confidence and potentially drive the stock price up. However, the company missed on sales, which could offset the positive impact of the earnings beat and lead to a neutral or mixed market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100